Abstract:
A sterile suture anchor comprising a body with a distal end, tapered planar side walls and a dome shaped proximal end, a cross section of said body forming a triangular shape with at least one rounded end; and a suture aperture transversely cut through the body being dimensioned to hold at least one suture. An insertion tool for inserting the suture anchor through a substantially cylindrical bore hole in a live human bone and causing the suture anchor to be anchored comprises a handle, a hollow tube secured to the handle and a driver rod slidably mounted in the tube. The driver rod has a distal end defining an angled cam which engages a suture anchor mounted in said tube and rotates the suture anchor into a desired position for insertion into human tissue. A finger driver assembly is mounted on the handle and is secured to the driver and so that movement of the finger driver assembly causes the driver rod to be moved within the hollow tube causing the driver rod cam end to engage the suture anchor and turn the suture anchor in a predetermined orientation for anchoring in the bore hole.
Abstract:
A non-catalytic process for NOx concentrations in process streams wherein a reducing agent and a readily-oxidizable gas are injected into a NOx-containing process stream to reduce the concentration of the NOx-containing process stream while minimizing the carryover of the unreacted reducing agent.
Abstract translation:在工艺流中的NO x x浓度的非催化方法,其中将还原剂和容易氧化的气体注入含NO x的工艺流中以降低浓度 的含NO x的工艺流,同时最小化未反应的还原剂的残留。
Abstract:
In one embodiment, the methods and apparatuses include: sharing desktop content with an attendee device wherein the desktop content corresponds with a presenter device and wherein the desktop content includes a hidden window; preventing the attendee device from viewing the hidden window; displaying the desktop content including the hidden window on the presenter device; and displaying the desktop content excluding the hidden window on the attendee device.
Abstract:
In one embodiment, the methods and apparatuses include: sharing desktop content with an attendee device wherein the desktop content corresponds with a presenter device and wherein the desktop content includes a hidden window; preventing the attendee device from viewing the hidden window; displaying the desktop content including the hidden window on the presenter device; and displaying the desktop content excluding the hidden window on the attendee device.
Abstract:
Toll Like Receptor 3 (TLR3) antagonists, polynucleotides encoding TLR3 antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.
Abstract:
Provided herein are certain compounds of Formula I: that can be used to treat diseases of proliferating cells. The compounds are KSP kinesin inhibitors, particularly inhibitors of human KSP.
Abstract:
The invention is a device used to measure and mark floor tile that must be cut to fit around obstructions. A key feature of the invention is that it has removable elements that make it possible to use the device with tile of any size. A second key feature is a plurality of telescoping members that can be extended to varying lengths in order to describe the perimeter geometry that must be duplicated by cutting away a portion of the tile. The invention is compatible with all tile and similar flat floor or wall coverings, such as pavers or carpet squares.
Abstract:
The present invention relates to at least one novel human EPO mimetic hinge core mimetibody or specified portion or variant, including isolated nucleic acids that encode at least one EPO mimetic hinge core mimetibody or specified portion or variant, EPO mimetic hinge core mimetibody or specified portion or variants, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
Abstract:
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, including ankylosing spondylitis, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.